Harpoon Therapeutics is a clinical-stage immunotherapy company focused on the development of novel T-cell recruiting biologic therapies.
Harpoon Therapeutics has raised $100.0M in total funding. The most recent round was Post-IPO Equity. The last funding was announced in October 2023.
Harpoon Therapeutics's investors include RA Capital Management, Cormorant Asset Management, Lilly Asia Ventures, OrbiMed, UBS Asset Management.
Harpoon Therapeutics is headquartered in South San Francisco, United States.
Harpoon Therapeutics is a clinical-stage immunotherapy company focused on the development of novel T-cell recruiting biologic therapies.
Harpoon Therapeutics is at the Post-IPO Equity stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Harpoon Therapeutics — Funding & Investors." VCBacked, October 23, 2023, https://www.vcbacked.co/company/harpoon-therapeutics. Accessed July 19, 2026.
VCBacked. (2023). Harpoon Therapeutics — Funding & Investors. Retrieved July 19, 2026, from https://www.vcbacked.co/company/harpoon-therapeutics
{{cite web |title=Harpoon Therapeutics — Funding & Investors |url=https://www.vcbacked.co/company/harpoon-therapeutics |website=VCBacked |access-date=July 19, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated